A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) Summary The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer. Part 1 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and Part 2 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone.
View Eligibility Criteria Eligibility Criteria Inclusion Criteria: Diagnosis of primary myelofibrosis (PMF), post-essential thrombocythemia (ET) or post-polycythemia vera (PV) myelofibrosis Treatment-related toxicities from prior therapy resolved to Grade 1 or pre-treatment baseline or determined to be irreversible prior to study treatment Must agree to follow specific methods of contraception, if applicable Exclusion Criteria: Women who are pregnant or breastfeeding at screening Any significant acute or uncontrolled chronic medical illness Other protocol-defined inclusion/exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 60 Locations for this study
Moores Cancer Center-Clinical Trials Office - Hematology La Jolla California, 92093, United States
Hoag Memorial Hospital Presbyterian Newport Beach California, 92663, United States
More Info
Florida Cancer Specialists Lake Mary Drug Development Unit Lake Mary Florida, 32746, United States
More Info
Tulane University School of Medicine New Orleans Louisiana, 70112, United States
More Info
Tufts Medical Center Boston Massachusetts, 02111, United States
More Info
Massachusetts General Hospital Boston Massachusetts, 02114, United States
More Info
University of Massachusetts Medical School-Division of Hematology/Oncology Worcester Massachusetts, 01655, United States
More Info
University Of Michigan Ann Arbor Michigan, 48109, United States
More Info
John Theurer Cancer Center at Hackensack University Medical Center Hackensack New Jersey, 07601, United States
More Info
Levine Cancer Institute Charlotte North Carolina, 28204, United States
More Info
AHN West Penn Hospital Pittsburgh Pennsylvania, 15224, United States
More Info
Lifespan Cancer Institute Providence Rhode Island, 02906, United States
More Info
Medical University of South Carolina Charleston South Carolina, 29425, United States
More Info
Mays Cancer Center San Antonio Texas, 78229, United States
Local Institution - 0036 Blacktown New South Wales, 2148, Australia
More Info
Local Institution - 0032 Wollongong New South Wales, 2500, Australia
More Info
Local Institution - 0007 East Melbourne Victoria, 3002, Australia
More Info
Local Institution - 0006 Heidelberg Victoria, 3084, Australia
More Info
Local Institution - 0041 Nedlands Western Australia, 6009, Australia
More Info
Local Institution - 0015 West Perth Western Australia, 6005, Australia
More Info
Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan-Institut de cancérologie et héma Brest , 29200, France
More Info
Institut Paoli-Calmettes-Hematology Marseille , 13273, France
More Info
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Hematology Nice , 06202, France
More Info
Hôpital Saint-Louis-Centre d'Investigations Cliniques Paris , 75010, France
More Info
Gustave Roussy-DITEP Villejuif , 94800, France
More Info
Local Institution - 0039 Essen Nordrhein-Westfalen, 45122, Germany
More Info
Local Institution - 0040 Chemnitz Sachsen, 09116, Germany
More Info
Local Institution - 0050 Lübeck Schleswig-Holstein, 23538, Germany
More Info
Local Institution - 0068 Erding , 85435, Germany
More Info
Local Institution - 0035 Halle (Saale) , 06120, Germany
More Info
Local Institution - 0061 Chaidari AttikÃ, 12462, Greece
More Info
Local Institution - 0047 Thessaloniki ThessalonÃki, 570 1, Greece
More Info
Local Institution - 0086 Be'er Sheva HaDarom, 84101, Israel
More Info
Local Institution - 0016 Jerusalem , 91120, Israel
More Info
Local Institution - 0018 Petah-Tikva , 49100, Israel
More Info
Local Institution - 0017 Ramat Gan , 52621, Israel
More Info
Local Institution - 0019 Tel Aviv , 64239, Israel
More Info
Local Institution - 0003 Bologna , 40138, Italy
More Info
Local Institution - 0002 Brescia , 25123, Italy
More Info
Local Institution - 0001 Firenze , 50134, Italy
More Info
Local Institution - 0012 Verona , 37134, Italy
More Info
Local Institution - 0049 Seongnam KyÇ’nggi-do, 13620, Korea, Republic of
More Info
Local Institution - 0048 Seoul Seoul-teukbyeolsi [Seoul], 05505, Korea, Republic of
More Info
Local Institution - 0053 Seoul Seoul-teukbyeolsi [Seoul], 06591, Korea, Republic of
More Info
Local Institution - 0063 Kraków Małopolskie, 31-50, Poland
More Info
Local Institution - 0077 Słupsk Pomorskie, 76-20, Poland
More Info
Local Institution - 0052 Bucuresti Cluj, 02232, Romania
More Info
Local Institution - 0083 București , 05009, Romania
More Info
Local Institution - 0051 Cluj , 40001, Romania
More Info
Local Institution - 0020 Badalona Barcelona [Barcelona], 08916, Spain
More Info
Local Institution - 0054 Madrid Madrid, Comunidad De, 28034, Spain
More Info
Local Institution - 0026 Madrid , 28041, Spain
More Info
Local Institution - 0021 Salamanca , 37007, Spain
More Info
Local Institution - 0029 Santander , 39008, Spain
More Info
Local Institution - 0094 València , 46026, Spain
More Info
Local Institution - 0088 Stanbul İstanbul, 34214, Turkey
More Info
Local Institution - 0079 Ankara , 06100, Turkey
More Info
Local Institution - 0080 Ankara , 06200, Turkey
More Info
Local Institution - 0089 İzmir , 35100, Turkey
More Info
Local Institution - 0081 Izmir , 35340, Turkey
More Info How clear is this clinincal trial information?